

10/056828

FILE 'REGISTRY' ENTERED AT 12:32:15 ON 04 NOV 2002

E FRUCTOYRANOSE SULFAMATE/CN 5

E TOPIRAMATE/CN 5

L1 1 S E3

E EPOETIN ALFA/CN 5

L3 1 S E3

L9 401 S ERYTHROPOIETIN?/CN

L10 402 S L3 OR L9

FILE 'HCAPLUS' ENTERED AT 12:35:51 ON 04 NOV 2002

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON TOPIRAMATE/CN

L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "EPOETIN ALFA"/CN

L5 423 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR (FRUCTOPYRANOSE
OR FRUCTO PYRANOSE) (W) (SULFAMATE OR SULPHAMATE) OR
TOPIRAMATE

L9 401 SEA FILE=REGISTRY ABB=ON PLU=ON ERYTHROPOIETIN?/CN

L10 402 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L9

L11 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (L10 OR ERYTHROPO
IETIN OR EPOETIN ALFA)

L11 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:637475 HCAPLUS

DOCUMENT NUMBER: 137:163821

TITLE: Treatment of neurological dysfunction comprising
fructopyranose sulfamates and
erythropoietin

INVENTOR(S): Plata, Salaman Carlos; Smith-Swintosky, Virginia

PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064085	A2	20020822	WO 2002-US3096	20020124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-266194P P 20010202

OTHER SOURCE(S): MARPAT 137:163821

AB Co-therapy for the treatment of neurol. dysfunctions comprises
administration of one or more **fructopyranose**
sulfamates and **erythropoietin**. **Topiramate**

Searcher : Shears 308-4994

10/056828

and recombinant human EPO showed synergistic effect on neurite outgrowth of cortical neurons.

IT 11096-26-7, Erythropoietin 97240-79-4,
Topiramate 113427-24-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(treatment of neurol. dysfunction comprising
fructopyranose sulfamates and
erythropoietin)

L11 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:556104 HCAPLUS

DOCUMENT NUMBER: 137:109489

TITLE: Compositions comprising a polypeptide and an
active agent

INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk,
Randal J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 34 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002099013	A1	20020725	US 2001-933708	20010822
PRIORITY APPLN. INFO.:			US 2000-247556P	P 20001114
			US 2000-247558P	P 20001114
			US 2000-247559P	P 20001114
			US 2000-247560P	P 20001114
			US 2000-247561P	P 20001114
			US 2000-247594P	P 20001114
			US 2000-247595P	P 20001114
			US 2000-247606P	P 20001114
			US 2000-247607P	P 20001114
			US 2000-247608P	P 20001114
			US 2000-247609P	P 20001114
			US 2000-247610P	P 20001114
			US 2000-247611P	P 20001114
			US 2000-247612P	P 20001114
			US 2000-247620P	P 20001114
			US 2000-247621P	P 20001114
			US 2000-247634P	P 20001114
			US 2000-247635P	P 20001114
			US 2000-247698P	P 20001114
			US 2000-247699P	P 20001114
			US 2000-247700P	P 20001114
			US 2000-247701P	P 20001114
			US 2000-247702P	P 20001114
			US 2000-247797P	P 20001114
			US 2000-247798P	P 20001114
			US 2000-247799P	P 20001114
			US 2000-247800P	P 20001114
			US 2000-247801P	P 20001114
			US 2000-247802P	P 20001114
			US 2000-247803P	P 20001114

Searcher : Shears 308-4994

10/056828

US 2000-247804P P 20001114
US 2000-247805P P 20001114
US 2000-247807P P 20001114
US 2000-247832P P 20001114
US 2000-247833P P 20001114
US 2000-247926P P 20001114
US 2000-247927P P 20001114
US 2000-247928P P 20001114
US 2000-247929P P 20001114
US 2000-247930P P 20001114

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalixin hydrochloride.

IT 97240-79-4, Topiramate 113427-24-0,
Epoetin alfa

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

L11 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:332011 HCAPLUS

DOCUMENT NUMBER: 136:355482

TITLE: Compositions comprising a polypeptide and an active agent

INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.

PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2001086599 A5 20020506 AU 2001-86599 20010822

PRIORITY APPLN. INFO.: US 2000-642820 A 20000822

WO 2001-US26142 W 20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring

10/056828

amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalixin hydrochloride.

IT 97240-79-4, Topiramate 113427-24-0,

Epoetin alfa

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. comprising a polypeptide and an active agent)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L11 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396644 HCAPLUS

DOCUMENT NUMBER: 135:24671

TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 1999-447690 A 19991123
WO 2000-US32255 W 20001122

AB The present invention provides solid pharmaceutical comps. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical compn. includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The comps. of the present invention can be used for improved delivery of

10/056828

hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A compn. contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT 97240-79-4, Topiramate 113427-24-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN
THE RE FORMAT

L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:300514 HCAPLUS

DOCUMENT NUMBER: 134:331617

TITLE: Oil-in-water emulsion compositions for
polyfunctional active ingredients

INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002107265	A1	20020808	US 1999-420159	19991018

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aq. phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepd., with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The compn. contained (by wt.) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

10/056828

IT 97240-79-4, Topiramate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)

IT 11096-26-7, Epoetin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; oil-in-water emulsion compns. for polyfunctional active ingredients)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN
THE RE FORMAT

L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON TOPIRAMATE/CN
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "EPOETIN ALFA"/CN
L5 423 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR (FRUCTOPYRANOSE
OR FRUCTO PYRANOSE) (W) (SULFAMATE OR SULPHAMATE) OR
TOPIRAMATE
L9 401 SEA FILE=REGISTRY ABB=ON PLU=ON ERYTHROPOIETIN?/CN
L10 402 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L9
L12 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (L10 OR ERYTHROPO
IETIN OR EPOETIN)

=> s l12 not l11

L13 0 L12 NOT L11

(FILE MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO' ENTERED AT 12:39:32 ON 04 NOV 2002)

L14 8 S L12

L15 5 DUP REM L14 (3 DUPLICATES REMOVED)

L15 ANSWER 1 OF 5 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2002414413 IN-PROCESS
DOCUMENT NUMBER: 22159038 PubMed ID: 12168506
TITLE: Gateways to Clinical Trials. June 2002.
AUTHOR: Bayes M; Rabasseda X; Prous J Rmbayes@prous.com
SOURCE: METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL
PHARMACOLOGY, (2002 Jun) 24 (5) 291-327.
Journal code: 7909595. ISSN: 0379-0355.
PUB. COUNTRY: Spain
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20020810
Last Updated on STN: 20020810

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, <http://integrity.prous.com>. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, alicaforsen sodium, almotriptan, alteplase, amlodipine, amoxicillin trihydrate, amprenavir, argatroban monohydrate, aspirin, atorvastatin calcium, azathioprine; Baclofen, benidipine hydrochloride, benserazide, BMS-214662, bosentan, botulinum toxin type B; Candesartan cilexetil, carbamazepine, carbidopa, carboplatin, ceftriaxone sodium, celecoxib, cetirizine hydrochloride, clarithromycin, clavulanate potassium, clopidogrel

hydrogensulfate, clozapine, CPI-1189, cyclophosphamide, cytarabine; Darbepoetin alfa, denileukin diftitox, dexamethasone, dipyridamole, droperidol, DW-166HC; Ebastine, efalizumab, efavirenz, eletriptan, enalapril maleate, enfuvirtide, enoxaparin sodium, enrasentan, entacapone, **epoetin**, eprosartan mesilate, etanercept, etoricoxib; Fenofibratefexofenadine hydrochloride, filgrastim, fludarabine phosphate, fluoxetine hydrochloride fluvoxamine maleate, frovatriptan, furosemide; Gabapentin, galantamine hydrobromide, gatifloxacin, gefitinib, ghrelin (human), glatiramer acetate; Haloperidol; Ibuprofen, ibuprofen, guaiacol ester, idarubicin hydrochloride, imipramine hydrochloride, imiquimod, interferon beta, interferon beta-1a, interferon beta-1b, interferon omega, irbesartan, itraconazole; Ketorolac, ketorolac tromethamine; Lamifiban, lamotrigine, lanoteplase, lansoprazole, leflunomide, leuporelin acetate, levetiracetam, levocetirizine, levodopa, lisinopril, loratadine; Manidipine, methylprednisolone, metronidazole, mirtazapine, mizolastine, modafinil, morphine sulfate; Naproxen sodium, naratriptan hydrochloride, nifedipine, NSC-683864; Ofloxacin, olanzapine, omalizumab, omapatrilat, ondansetron hydrochloride, oxcarbazepine; Paclitaxel, parecoxib sodium, paroxetine hydrochloride, phenytoin sodium, pimecrolimus, pramipexole hydrochloride, pravastatin, prednisone, pregabalin; Quetiapine fumarate; Ranitidine hydrochloride, rasburicase, ritonavir, rivastigmine tartrate, rizatriptan benzoate, rofecoxib; Saquinavir mesilate, sertraline, sildenafil citrate, simvastatin, sumatriptan succinate; Tacrolimus, tiagabine hydrochloride, ticlopidine hydrochloride, tirofiban hydrochloride, tolvaptan, **topiramate**, tretinoin; Valproic acid, valsartan, venlafaxine hydrochloride, verapamil; Warfarin sodium; Ximelagatran; Zanamivir, ziconotide, zolmitriptan, zonisamide.

L15 ANSWER 2 OF 5 SCISEARCH COPYRIGHT 2002 ISI (R)

ACCESSION NUMBER: 2002:364309 SCISEARCH

THE GENUINE ARTICLE: 543BL

TITLE: Gateways to clinical trials - March 2002

AUTHOR: Bayes M (Reprint); Rabasseda X; Prous J R

SOURCE: METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (MAR 2002) Vol. 24, No. 2, pp. 95-118. Publisher: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0379-0355.

DOCUMENT TYPE: General Review; Journal

LANGUAGE: English

REFERENCE COUNT: 134

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Gateways to Clinical Trials is a guide to the most recent clinical trials ill current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development portal, and provides information on study design, treatments, conclusions and references. This issue focuses oil the following selection of drugs: Alefacept, alendronic acid sodium salt, alteplase, amediplate, aminolevulinic acid hydrochloride, amitriptyline hydrochloride, amlodipine, amoxicillin sodium, amoxicillin trihydrate, amprenavir, amtolmetin guacil, argatroban monohydrate, aspirin, atorvastatin calcium, avasimibe, azelastine hydrochloride; Beclometasone dipropionate, botulinum toxin type A: Calcipotriol, candesartan cilexetil, capecitabine,

10/056828

cefaalexin, celecoxib, cerivastatin sodium, cetirizine hydrochloride, citalopram hydrobromide, clarithromycin, clobetasol propionate, colestyramine, conivaptan hydrochloride; Darbepoetin alfa, desloratadine, dexamethasone, diclofenac sodium, dihydrocodeine bitartrate, DNK-333A; Efalizimab, elinafide mesilate, emtricitabine, enalapril maleate, enoxaparin sodium, eplerenone, **epoetin**, esomeprazole magnesium, etanercept, ezetimibe; Factor VIII gene therapy, fenofibrate, fexofenadine hydrochloride, fondaparinux sodium, furosemide; Gemifloxacin mesilate; Heparin sodium hydrocortisone, hydrochlorothiazide; Ibuprofen, IDEC-131, imatinib mesilate, imiquimod, iodine (I131) tositumomab, irbesartan, iseganan hydrochloride; Lanoteplase, lansoprazole, L-Arginine hydrochloride, loratadine, losartan potassium, lovastatin; Magnesium sulfate, maxacalcitol, metformin hydrochloride, methotrexate, micafungin sodium, mifepristone, morphine sulfate; Naproxen sodium, niacin, nitrendipine, nolumirole hydrochloride, NSC-703940; Olmesartan medoxomil, omalizumab, omapatrilat, omeprazole, omeprazole sodium, oritavancin; Paroxetine, pegvisomant, pethidine hydrochloride, pimecrolimus, piroxicam, pravastatin sodium, prednisone; Quinapril hydrochloride; Ranolazine, rifabutin, rifampicin, rofecoxib, rosiglitazone maleate, rosuvastatin calcium; Sch-48461, Simvastatin; Tacrolimus, telmisartan, tenecteplase, thalidomide, **topiramate**, tramadol hydrochloride, triamcinolone acetonide, troglitazone; Ubidecarenone; Valsartan, vancomycin hydrochloride; Warfarin sodium; Ximelagatran. (C) 2002 Prous Science. All rights reserved.

L15 ANSWER 3 OF 5 WPIDS (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: 2001-475649 [51] WPIDS

DOC. NO. CPI: C2001-142565

TITLE: Solid composition for delivery of active agents
e.g. glyburide comprises carrier optionally
containing a substrate having an encapsulation coat
containing hydrophilic surfactants e.g.
polyoxyethylene alkylethers.

DERWENT CLASS: A96 B05 B07

INVENTOR(S): CHEN, F; PATEL, M V

PATENT ASSIGNEE(S): (LIPO-N) LIPOCINE INC

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO	2001037808	A1	20010531	(200151)*	EN 106
----	------------	----	----------	-----------	--------

RW:	AT	BE	CH	CY	DE	DK	EA	ES	FI	FR	GB	GH	GM	GR	IE	IT	KE	LS	LU	MC
MW	MZ	NL	OA	PT	SD	SE	SL	SZ	TR	TZ	UG	ZW								

W:	AE	AG	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	BZ	CA	CH	CN	CR	CU	CZ	DE
	DK	DM	DZ	EE	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN	IS	JP	KE	KG
	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MA	MD	MG	MK	MN	MW	MX	MZ	NO	NZ
	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	TZ	UA	UG	UZ	VN	YU
	ZA	ZW																		

US	6248363	B1	20010619	(200151)	
----	---------	----	----------	----------	--

AU	2001017981	A	20010604	(200153)	
----	------------	---	----------	----------	--

EP	1233756	A1	20020828	(200264)	EN
----	---------	----	----------	----------	----

R:	AL	AT	BE	CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LI	LT	LU	LV	MC	MK
	NL	PT	RO	SE	SI	TR														

APPLICATION DETAILS:

Searcher : Shears 308-4994

10/056828

PATENT NO	KIND	APPLICATION	DATE
WO 2001037808	A1	WO 2000-US32255	20001122
US 6248363	B1	US 1999-447690	19991123
AU 2001017981	A	AU 2001-17981	20001122
EP 1233756	A1	EP 2000-980761	20001122
		WO 2000-US32255	20001122

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001017981	A Based on	WO 200137808
EP 1233756	A1 Based on	WO 200137808

PRIORITY APPLN. INFO: US 1999-447690 19991123

AN 2001-475649 [51] WPIDS

AB WO 200137808 A UPAB: 20021031

NOVELTY - Composition for improved delivery of active agent comprising a solid carrier optionally containing a substrate having an encapsulation coat, where the solid carrier or encapsulation coat contains at least one active agent (I) and one hydrophilic surfactant (II), is new.

ADVANTAGE - The composition is used to deliver a wide variety of active agents having improved absorption and/or bioavailability. It provides coated substrate materials without the need for binders. Prior art solid carriers are limited to a few specific drugs due to difficulties in formulating appropriate drug/excipient compositions to effectively coat the active agent onto a carrier particle. Most of prior art solid dosage forms of hydrophilic active agents exhibit poor or no absorption of the active agent. Non-solid formulations of the same are chemically instable, leak and have capsule shell incompatibility. Conventional solid dosage forms of hydrophobic active agents often exhibit slow and incomplete dissolution and subsequent absorption. They often show a high propensity for biovariability and food interactions of the active agent, resulting in restrictive compliance/labeling requirements. A comparative dissolution study was performed on 3 forms of glyburide (Ia) namely coated beads of (Ia), commercially available (Ia) and pure (Ia) bulk. 5 mg Of each form was used for triplication dissolution runs in 500 ml of isotonic pH 7.4 phosphate buffer. The dissolution medium was sampled at 15, 30, 45, 60, 120 and 180 minutes. The samples were filtered and the filtrates diluted for (Ia)-specific HPLC assay. The (Ia)-coated beads showed a superior dissolution profile in the rate, extent and variability of (Ia) dissolved/released into the medium.

Dwg.0/3

L15 ANSWER 4 OF 5 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2002003764 EMBASE

TITLE: Current FDA-related drug information: New drugs approved by the FDA. New dosage forms and indications - Agents pending FDA approval - Labeling changes related to safety.

AUTHOR: Baker D.E.

CORPORATE SOURCE: Dr. D.E. Baker, Drug Information Center, College of Pharmacy, Washington State University, 601 West First

10/056828

SOURCE: Avenue, Spokane, WA 99201-3899, United States
Hospital Pharmacy, (2001) 36/12 (1278-1289).
ISSN: 0018-5787 CODEN: HOPHAZ

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy

LANGUAGE: English

L15 ANSWER 5 OF 5 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000046771 EMBASE

TITLE: New drugs approved by the FDA: New dosage forms and
indications agents pending FDA approval: Major
labeling changes.

AUTHOR: Baker D.E.

CORPORATE SOURCE: D.E. Baker, Drug Information Center, College of
Pharmacy, Washington State University, 601 West First
Avenue, Spokane, WA 99201-3899, United States.
Hospitalpharmacy@drugfacts.com

SOURCE: Hospital Pharmacy, (2000) 35/1 (87-98).
ISSN: 0018-5787 CODEN: HOPHAZ

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: English

=> fil hom

FILE 'HOME' ENTERED AT 12:47:34 ON 04 NOV 2002